18,516 Shares in Moderna, Inc. (NASDAQ:MRNA) Bought by WINTON GROUP Ltd

WINTON GROUP Ltd bought a new stake in shares of Moderna, Inc. (NASDAQ:MRNA - Free Report) during the 4th quarter, according to the company in its most recent disclosure with the SEC. The fund bought 18,516 shares of the company's stock, valued at approximately $770,000.

A number of other institutional investors also recently added to or reduced their stakes in the business. State Street Corp raised its holdings in Moderna by 12.1% during the third quarter. State Street Corp now owns 16,847,212 shares of the company's stock worth $1,125,899,000 after purchasing an additional 1,823,276 shares in the last quarter. Geode Capital Management LLC raised its stake in shares of Moderna by 2.6% in the 3rd quarter. Geode Capital Management LLC now owns 7,069,580 shares of the company's stock worth $470,670,000 after buying an additional 178,115 shares in the last quarter. Wellington Management Group LLP lifted its holdings in shares of Moderna by 21.0% in the third quarter. Wellington Management Group LLP now owns 5,224,685 shares of the company's stock valued at $349,166,000 after buying an additional 906,114 shares during the period. UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC boosted its stake in Moderna by 0.5% during the third quarter. UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC now owns 3,890,812 shares of the company's stock valued at $260,023,000 after buying an additional 19,819 shares in the last quarter. Finally, Charles Schwab Investment Management Inc. grew its holdings in Moderna by 9.9% during the fourth quarter. Charles Schwab Investment Management Inc. now owns 2,344,203 shares of the company's stock worth $97,472,000 after acquiring an additional 211,426 shares during the period. Institutional investors and hedge funds own 75.33% of the company's stock.

Remove Ads

Wall Street Analyst Weigh In

MRNA has been the subject of several research reports. Bank of America reduced their price objective on shares of Moderna from $41.00 to $34.00 and set an "underperform" rating for the company in a research report on Tuesday, February 11th. Berenberg Bank lifted their target price on Moderna from $33.00 to $42.00 and gave the stock a "hold" rating in a report on Thursday, January 16th. Morgan Stanley cut their price target on shares of Moderna from $70.00 to $38.00 and set an "equal weight" rating on the stock in a report on Wednesday, January 15th. Citigroup initiated coverage on shares of Moderna in a research note on Thursday, March 13th. They issued a "neutral" rating and a $40.00 price objective for the company. Finally, Royal Bank of Canada restated a "sector perform" rating and issued a $40.00 target price on shares of Moderna in a report on Tuesday, February 18th. Four research analysts have rated the stock with a sell rating, sixteen have assigned a hold rating, three have assigned a buy rating and one has given a strong buy rating to the company's stock. According to data from MarketBeat, the company has an average rating of "Hold" and a consensus target price of $59.00.

Moderna Trading Down 4.2 %

Moderna stock traded down $1.19 during mid-day trading on Tuesday, hitting $27.16. 11,625,208 shares of the company's stock were exchanged, compared to its average volume of 6,890,880. Moderna, Inc. has a 1-year low of $26.80 and a 1-year high of $170.47. The stock has a 50 day moving average of $34.60 and a two-hundred day moving average of $43.84. The stock has a market cap of $10.50 billion, a P/E ratio of -2.93 and a beta of 1.86.

Moderna Profile

Moderna, Inc, a biotechnology company, discovers, develops, and commercializes messenger RNA therapeutics and vaccines for the treatment of infectious diseases, immuno-oncology, rare diseases, autoimmune, and cardiovascular diseases in the United States, Europe, and internationally. Its respiratory vaccines include COVID-19, influenza, and respiratory syncytial virus, spikevax, and hMPV/PIV3 vaccines; latent vaccines comprise cytomegalovirus, epstein-barr virus, herpes simplex virus, varicella zoster virus, and human immunodeficiency virus vaccines; public health vaccines consists of Zika, Nipah, Mpox vaccines; and infectious diseases vaccines, such as lyme and norovirus vaccines.